Indianapolis, IN, United States of America

Jonathan Wendell Tetreault



 

Average Co-Inventor Count = 5.5

ph-index = 2

Forward Citations = 30(Granted Patents)


Company Filing History:


Years Active: 2010-2012

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Jonathan Wendell Tetreault

Introduction

Jonathan Wendell Tetreault is an accomplished inventor based in Indianapolis, IN. He has made significant contributions to the field of biotechnology, particularly in the development of antibodies for therapeutic applications. With a total of 2 patents, Tetreault's work focuses on addressing critical health issues through innovative solutions.

Latest Patents

Tetreault's latest patents involve Anti-IL-17 antibodies. These antibodies are characterized by their high affinity and slow off rate for human IL-17. The invention includes chimeric, humanized, or fully human antibodies, as well as immunoconjugates of the antibodies or antigen-binding fragments. These antibodies are particularly useful in treating autoimmune, inflammatory, cell proliferative, and developmental disorders.

Career Highlights

Tetreault is currently employed at Eli Lilly and Company, a leading pharmaceutical company known for its commitment to innovation in healthcare. His work at Eli Lilly has allowed him to contribute to groundbreaking research and development in the field of immunology.

Collaborations

Some of Tetreault's notable coworkers include Barrett Allan and Chi-Kin Chow. Their collaborative efforts have further advanced the research and development of therapeutic antibodies.

Conclusion

Jonathan Wendell Tetreault's contributions to the field of biotechnology through his patents and work at Eli Lilly and Company highlight his dedication to improving healthcare solutions. His innovative approach to developing Anti-IL-17 antibodies showcases the potential for advancements in treating various disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…